[Advances in the diagnosis and treatment of patients with multidrug-resistant bacterial infections combined with severe liver disease].

作者：X L Lu, W C Xu, H R Ke, Q H Cheng, B L Li, J J Chen · 发表于：PubMed · 年份：2026 · DOI：10.3760/cma.j.cn501113-20251107-00481 · 研究领域：Drug-Induced Hepatotoxicity and Protection、Silymarin and Mushroom Poisoning、Flavonoids in Medical Research

Effective antibiotic treatment is crucial for patients with severe liver disease combined with bacterial infections in the early stage. However, the incidence rate of multidrug-resistant bacteria (MDROs) infection in such patients is as high as 34%, and it is increasing year by year, becoming one of the main causes of antibiotic treatment failure and patient mortality. The main common MDROs in clinical practice are methicillin-resistant Staphylococcus aureus, carbapenem-resistant Enterobacteriaceae, vancomycin-resistant Enterococcus, and extended-spectrum β-lactamase-producing Enterobacteriaceae, with limited antimicrobial therapeutic options. Therefore, research on the diagnosis and treatment of MDRO infection can significantly improve the prognosis of patients with severe liver disease. The main risk factors for MDRO infections in these patients include frequent hospitalizations, invasive procedures, MDRO colonization, and repeated exposure to antimicrobial agents. The key measures to reduce MDRO infection are to strengthen nosocomial infection control, use antimicrobial agents rationally, conduct epidemiological surveillance, and actively screen colonized patients.